Insulet Stock Price, News & Analysis (NASDAQ:PODD)

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 5 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PODD shares.
View PODD analyst ratings or view top-rated stocks.

17 brokerages have issued 12-month price objectives for Insulet's shares. Their PODD share price targets range from $162.00 to $350.00. On average, they predict the company's stock price to reach $258.07 in the next year. This suggests a possible upside of 32.7% from the stock's current price.
View analysts price targets for PODD or view top-rated stocks among Wall Street analysts.

Insulet's stock was trading at $294.39 on January 1st, 2023. Since then, PODD shares have decreased by 33.9% and is now trading at $194.54.
View the best growth stocks for 2023 here.

Insulet saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 5,370,000 shares, an increase of 65.7% from the October 31st total of 3,240,000 shares. Based on an average daily trading volume, of 1,480,000 shares, the days-to-cover ratio is currently 3.6 days.
View Insulet's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our PODD earnings forecast.

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings data on Thursday, November, 2nd. The medical instruments supplier reported $0.71 earnings per share for the quarter, beating analysts' consensus estimates of $0.40 by $0.31. The medical instruments supplier had revenue of $432.70 million for the quarter, compared to analyst estimates of $413.82 million. Insulet had a trailing twelve-month return on equity of 23.98% and a net margin of 7.71%.

ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include Fidelity Digital Health ETF (FDHT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco Focused Discovery Growth ETF (IVDG), Harbor Health Care ETF (MEDI), Fidelity Disruptive Medicine ETF (FMED), VictoryShares Nasdaq Next 50 ETF (QQQN) and Nuveen ESG Mid-Cap Growth ETF (NUMG).

Insulet updated its third quarter 2023 earnings guidance on Tuesday, October, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $402.14 million-$412.37 million, compared to the consensus revenue estimate of $414.30 million.

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

Insulet's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Clearbridge Investments LLC (2.05%), William Blair Investment Management LLC (1.05%), Primecap Management Co. CA (0.98%), Northern Trust Corp (0.98%), Westfield Capital Management Co. LP (0.91%) and Bank of New York Mellon Corp (0.70%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, James Hollingshead, John A Fallon, Luciana Borio, Michael P Spears, Prem Singh, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends.

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.